IL17A and metabolic dysfunction-associated steatohepatitis: CHC patients, as well as CHC-NSF and CHC-SF patients, were distinguished from NASH patients according to lower concentrations of plasma IL-17A (p = 0.007, p = 0.004 and p = 0.021, respectively).